The present invention relates generally to systems and methods for delivering a medicament that is associated with an implant.
Implants, such as orthopaedic implants or stents, in a patient may become infected after implantation. For example, infectious cells, such as bacteria cells, may form around the implant or attach to the implant. In addition, infectious cells may form a layer of material or biofilm over themselves to protect the infectious cells from medicaments, such as antibiotics, meant to kill or disrupt the infectious cells. To treat the infected area, health-care providers often remove the implant, apply a medicament, such as an antibiotic, to the infected area, and re-implant the implant.
Health-care providers can supplement removing the implant by introducing a medicament systemically, such as providing the patient with a medicament in pill form that the patient orally ingests, or by injecting a medicament directly into, or in proximity to, the infected area. In some instances, a medicament is attached to the implant and released when exposed to body tissue after re-implantation.
Such treatment procedures are sometimes unsuccessful due to complications or infections that return at a later time. Additional infections may also occur when the health-care provider removes and re-implants the implant. Physiologic phenomenon, such as infectious cells forming a biofilm that protects the cells from a medicament released just after implantation, may prevent or inhibit a medicament delivered by such treatment procedures from effectively treating the infection. Furthermore, a medicament delivery system that releases a medicament at the same time, or shortly after, implantation may not effectively treat the infected area or infectious cells that develop at a period of time after implantation.
Accordingly, a need exists for a medicament delivery system and method that can release a medicament at a time selected by a health-care professional. A need further exists for a medicament delivery method that can release a medicament at a selected time without requiring the removal of an implant. A need further exists for a medicament delivery system and method that provides for delivery a medicament at a customizable time and/or rate selected by a health-care professional.
Aspects and embodiments of the present invention provide methods and systems for delivering a medicament at a level selected by an energy source user, such as a health-care professional. In one embodiment of the present invention, a medicament containment device containing a medicament, such as for example an antibiotic, is attached to an implant that may be an orthopaedic implant or stent. The medicament containment device can degrade upon exposure to energy, such as energy from an energy source. The implant, including the medicament containment device, is implanted or inserted into an environment such as a patient's body. An energy source can be used outside the patient's body, but in proximity to the implant, to apply energy to the medicament containment device. Upon exposure to the energy, the medicament containment device can disintegrate, degrade, or otherwise alter in structure or composition or both, partially or totally, sufficient to allow a medicament to penetrate (hereinafter “degrade”) and release at least part of the medicament into the environment. The medicament can kill and/or disrupt bacterial cells or other infectious cells that form in proximity to the implant.
In some embodiments of the present invention, the medicament containment device may include at least a first layer and a second layer. The first layer can substantially surround the second layer. The second layer can substantially surround a medicament. The first layer can degrade upon exposure to energy from an energy source and expose the second layer to the environment. The second layer can be a resorbable layer that, when exposed to the environment, degrades over time and substantially releases the medicament.
In some embodiments of the present invention, an energy source is provided that is adapted to apply energy to bacteria cells attached to or around an implant and kill or disrupt the bacteria cells. The energy may also disrupt a bacteria film to allow a medicament delivered using any desired method to kill the bacteria cells.
According to an aspect of the present invention, there may be provided a medicament containment device for association with an implant, the medicament containment device comprising a medicament, a first layer substantially surrounding a second layer, the second layer substantially surrounding the medicament, wherein the first layer is adapted to at least partially degrade when the first layer is exposed to energy from an energy source, and wherein the second layer is adapted to at least partially degrade and release at least part of the medicament after the first layer degrades.
According to one embodiment of the present invention, the first layer at least partially exposes the second layer to an environment and the second layer is a resorbable layer and is adapted to at least partially degrade after exposure to the environment.
According to one embodiment of the present invention, the medicament containment device further comprises a first medicament between the first layer and the second layer, wherein the medicament substantially surrounded by the second layer is a second medicament.
According to one embodiment of the present invention, the first layer is adapted to degrade at a first resonant frequency and the second layer is adapted to degrade at a second resonant frequency.
According to one embodiment of the present invention, the implant is a resorbable implant adapted to degrade over a period of time and the medicament is a resorbtion acceleration agent and the resorbtion acceleration agent is adapted to increase the rate of degradation by the resorbable implant.
According to one embodiment of the present invention, the energy is at least one of an ultrasound wave, thermal, light wave, radar, sonar, ultraviolet light wave, microwave, electrical, magnetic field, vibratory, and laser.
According to one embodiment of the present invention, the implant is an orthopaedic implant.
According to an aspect of the present invention, a method is provided for delivering a medicament from a medicament containment device, the medicament containment device having at least one layer containing the medicament, the method comprising associating the medicament containment device with an implant, the implant being implanted into a patient body, applying energy to the medicament containment device, at least partially degrading the at least one containment device layer with the applied energy, and releasing the medicament from the medicament containment device after the at least one layer at least partially degrades.
According to one embodiment of the present invention, the method further comprises providing the medicament containment device having a first layer and a second layer, the first layer substantially surrounding the second layer and the second layer substantially surrounding the medicament.
According to one embodiment of the present invention, the method further comprises at least partially degrading the first layer with the applied energy, at least partially degrading the second layer, and releasing the medicament from the medicament containment device after the second layer at least partially degrades.
According to one embodiment of the present invention, the method further comprises exposing the second layer to an environment after the first layer at least partially degrades and the second layer at least partially degrades after exposure to the environment.
According to one embodiment of the present invention, associating the medicament containment device with the implant comprises attaching the medicament containment device to the implant.
According to one embodiment of the present invention, attaching the medicament containment device to the implant comprises providing a pool comprising a plurality of medicament containment devices, applying an adhesive paste to the implant, and dipping the implant having adhesive paste into the pool.
According to one embodiment of the present invention, the method further comprises associating the medicament containment device with the implant comprises inserting the medicament containment device in proximity to the implant in a patient body.
According to one embodiment of the present invention, the at least one layer is a seal.
According to one embodiment of the present invention, the implant is an orthopaedic implant.
According to an aspect of the present invention, a system is provided comprising an energy source adapted to release energy, an implant in a patient body comprising a medicament containment device, the medicament containment device comprising a at least one layer comprising a medicament, wherein the energy is adapted to at least partially degrade the at least one layer, and wherein the medicament containment device is adapted to release at least part of the medicament after the at least one layer at least partially degrades.
According to one embodiment of the present invention, the energy source is located inside the patient body.
According to one embodiment of the present invention, the energy source is located outside the patient body.
According to one embodiment of the present invention, the medicament containment device comprises a well reservoir adapted to store the medicament, a seal, and wherein the seal is adapted to at least partially degrade after exposure to the energy.
According to one embodiment of the present invention, the energy is adapted to disrupt bacteria colonies around the orthopaedic implant.
According to one embodiment of the present invention, the medicament containment device comprises a first layer substantially surrounding a second layer, the second layer substantially surrounding the medicament, wherein the first layer is adapted to at least partially degrade when the first layer is exposed to energy from an energy source, and wherein the second layer is adapted to at least partially degrade and release at least part of the medicament after the first layer degrades.
According to one embodiment of the present invention, the system further comprises a first medicament between the first layer and the second layer, wherein the medicament substantially surrounded by the second layer is a second medicament.
According to one embodiment of the present invention, the first layer is adapted to degrade at a first resonant frequency and the second layer is adapted to degrade at a second resonant frequency.
According to one embodiment of the present invention, the energy source is adapted to release energy at the first resonant frequency and the second resonant frequency.
According to one embodiment of the present invention, the second layer is a resorbable layer that is adapted to at least partially degrade after exposure to body tissue.
According to one embodiment of the present invention, the implant is an orthopaedic implant.
‘Embodiment’ as used herein can be considered to mean an aspect or object of the invention, and vice versa.
These and other features, aspects, and advantages of the present invention are better understood when the following Detailed Description of the Invention is read with reference to the accompanying drawings, wherein:
Certain aspects and embodiments of the present invention provide a medicament delivery system and method that allows a medicament to be delivered to an environment, such as a patient's internal body, at a selected time after implantation of an implant into a patient's body.
The layer may be adapted to degrade or otherwise substantially release the medicament upon exposure to energy from an energy source. For example,
In some embodiments of the present invention, the layer degrades after exposure to energy at a resonant frequency. The energy source 14 may release energy 16 at the resonant frequency of the layer. One example of the energy 16 is an ultrasound signal at the resonant frequency of the layer. Other types of energy 16 may include thermal, light waves, radar, sonar, ultraviolet light waves, microwaves, electricity, magnetic fields, vibratory, and laser.
The energy source 14 may be outside or inside the patient's body. In one embodiment, the energy source 14 is a separate device outside the body that may, for example, allow a user to controllably release energy 16.
In another embodiment, the energy source 14 can be inserted and maintained within the patient's body. The energy source 14 could be self-sufficient within the patient's body, such that it requires no communication with or link to any device outside of the patient's body to apply energy 16 to the containment devices 12. The energy source 14 may also be attached, embedded or otherwise associated with the implant or another device inserted into the patient's body. In another embodiment, the energy source 14 can communicate with another device outside the patient's body through a wire or wirelessly. The device outside the patient's body could be used to control the energy source 14, such as when to apply energy 16 and the characteristics of the applied energy 16.
The energy source 14 may communicate with a separate device that channels, carries, and/or amplifies the applied energy 16. For example, energy 16 that is vibration energy can be carried by a material, such as a vibrating beam having a geometry adapted to direct or focus the energy 16 to the desired area. However, a carrier or amplification device may be used for any type of energy 16.
The containment device layer may include a first layer and a second layer. As described in more detail below, the first layer may be an outer layer that degrades upon exposure to the energy 16 and exposes the second layer to the environment 10. The second layer may be an inner layer that is resorbable, absorbable, or otherwise adapted to degrade over a period of time after exposure to the environment 10 to substantially release the medicament 18. The second layer may also have the same or different resonant frequency than the first layer. For example, the second layer may degrade upon exposure to energy at a different frequency than the energy 16 to substantially release the medicament. In other embodiments, the second layer has no resonant frequency.
In some embodiments, the first layer may substantially surround a first medicament layer, the second layer, and a second medicament layer. The second layer may substantially surround the second medicament layer. Upon exposure to the energy 16, the first layer can degrade and substantially release the first medicament layer. The second layer may then be exposed to an energy at the same or different frequency and degrade to substantially release the second medicament layer. The medicament layers may be different volumes to provide a health-care professional with additional options to deliver the desired amount and type of medicament.
Furthermore, the layer of each of the containment devices 12 may have different resonant frequencies. Each containment device 12 may release medicament at different resonant frequencies and allow a health-care professional to select when and how much medicament to release.
As stated above, medicament containment devices according to some embodiments of the present invention may be attached, embedded, or otherwise associated with an implant.
A bacteria colony 108 may form around the orthopaedic implant 102 after implantation as result of an infection. An energy source 110 that is located outside of the patient's body can be used to apply energy 112 to the containment devices 106 and substantially release medicament 114 to kill or otherwise disrupt the bacteria colony 108.
In some embodiments, the orthopaedic implant 102 may be a resorbable orthopaedic implant adapted to degrade after a period of time, such as after the orthopaedic implant is no longer needed to heal or otherwise treat a patient's injury. The containment devices 106 may contain a medicament that is a resorbtion acceleration agent adapted to increase the rate at which the orthopaedic implant 102 degrades. The energy source 110 may be used to apply energy 112 to the containment devices 106. Upon exposure to the energy 112, the containment devices 106 may degrade and substantially release the resorbtion acceleration agent to the environment 100. The resorbtion acceleration agent can interact with the resorbable orthopaedic implant and increase the rate at which the orthopaedic implant 102 degrades.
A first energy source 206, shown in
A second energy source 212, shown in
The first energy source 206 and second energy source 210 may be the same device adapted to release energy with at least two different characteristics. For example, energy 208 and energy 214 may be an ultrasound signal released at different frequencies. A user may use the second energy source 212 to release the second type of energy 214 at the same time or at a different time than the first type of energy 208.
Furthermore, any number of containment devices may be included in the environment 200 and each may substantially release medicament after exposure to energy with different characteristics. A user can select the amount and time for releasing the medicament based on the energy characteristics he or she applies to the containment devices. For example, the volume of released medicament may be controlled by the user by applying energy with selected characteristics at different times.
The second layer 310 of each containment device 302 substantially surrounds a medicament and can be a resorbable, absorbable, or other type of layer that can degrade over time after exposure to the environment 300. The second layer 310 may be adapted to incrementally degrade and substantially release the medicament 312 over a period of time.
An example of a medicament containment device 402 with two layers 404, 406 is shown
An additional medicament layer may be included between the first layer 404 and second layer 406. When the first layer 404 is exposed to energy 408 and degrades, the additional medicament layer can be substantially released into the environment 400 to kill and/or disrupt bacteria colonies. The second layer 406 may be a resorbable, absorbable, or other type of layer that degrades over a period of time after the additional medicament layer is substantially released. The medicament 412 is then substantially released after the second layer 406 at least partially degrades.
In some embodiments, the second layer 406 may degrade after exposure to energy having different characteristics than the energy 408 used to degrade the first layer 404. For example, energy 408 is applied to the containment device 402 and the first layer 404 degrades, exposing the second layer 406 to the environment 400. At the same or later time, a second type of energy from the same or different energy source may be applied to the containment device 402. The second layer 406 may be made with characteristics to degrade after exposure to the second type of energy and not the energy 408.
Medicament containment devices according to some embodiments of the present invention may be wells attached, embedded, or otherwise associated with an implant.
The well reservoirs 508, 512 can contain medicaments 514, 516 adapted to kill or otherwise disrupt a bacteria colony upon release into the environment. Energy 518 from an energy source 520 may be applied to the environment 500. The seals may break apart and substantially release the medicaments 514, 516 into the environment upon exposure to the energy 518. In some embodiments, the energy 518 breaks apart the seals and pumps the medicaments 514, 516 out of the well reservoirs 508, 512. For example, the energy 518 may be thermal energy that heats the medicaments 514, 516 to a level such that they exit the well reservoirs 508, 512 and into the environment 500. Alternatively, natural physical strain on the implant 501 can force medicament out of the well reservoirs 508, 512 after the seals are broken. Each of the seals may be configured to break apart after exposure to energy with different characteristics, such as for example different frequencies.
Medicament containment devices according to some embodiments of the present invention are not attached to or embedded with implants.
The containment devices 602 can contain medicaments that can kill or disrupt infectious cells, such as bacteria colony 606. The bacteria colony 606 may form around the implant 604 and/or attach to the implant 604. The bacteria colony 606 may include bacteria cells and a biofilm forming a barrier between the bacteria cells and the environment 600. The medicament containment devices 602 may be injected into the environment after or at the same time of implantation. Alternatively, the containment devices 602 can be introduced via oral ingestion by the patient or an intravenous therapy method.
An energy source 608 is provided in
Medicament containment devices according to some embodiments of the present invention may be made from any type of material, one example of which is self healing polymers including bone cement. Specifically, microcapsules may be filled with a liquid monomer and dispersed in an epoxy matrix. A catalyst is embedded in the epoxy that induces polymerisation of the encapsulated monomer. When a crack occurs through the cured material, the micro-capsules are broken open. Capillary action draws the monomer into the crack and exposes it to the catalyst. The monomer then polymerises. The polymerised material then binds two faces of the crack together. Other material that may be used to make the containment devices includes titanium, titanium alloys, steel, cobalt-chromium alloys, tantalum, magnesium, peek, polyethylene, bioglass, brushite, hydroxy-appetite, calcium sulfate, calcium phosphate, silicon oxide, silk, poly-alpha-hydroxy acids, polyglycols, polytyrosine carbonates, starch, gelatins, polysaccharides, polyurethanes, polyesters, polyphosphoesters, polyphosphates, polyphosphonates, modified protein, polyorthoesters, trimethylenecarbonate, polydioxanones, polycapropactones, cellulose, polylactides, polyglycolic acid, copolymers, or any combination of the above or other material.
The following is an example of a medicament delivery system and method according to one embodiment of the present invention. Medicament containment devices may include an outer layer surrounding an inner layer that surrounds an antibiotic medicament. The outer layer is made from polyethlyene, forming a layer that can at least partially degrade upon exposure to energy, such as ultrasonic energy. The inner layer is made from polylactic acid (PLA) isomers, forming a resorbable layer that at least partially degrades upon exposure to body tissue. The containment devices may be made to any size. For example, the containment devices can have dimensions of 0.2 mm to 5 mm long with a width of 0.2 mm to 5 mm. In one particular embodiment, the containment devices are 2 mm long with a width of 1 mm.
A pool of containment devices is collected and a sterilized intermedullary plate orthopaedic implant is covered with an adhesive paste and dipped into the pool of containment devices. The containment devices are attached to the orthopaedic implant via the adhesive paste. Alternatively, the orthopaedic implant may be un-sterilized when dipped into the pool of containment devices and then the orthopaedic implant with attached containment devices is sterilized. After the adhesive paste solidifies, the orthopaedic implant is packaged into a vacuum pack with an insulation layer around the pack, at least in part, to prevent energy from degrading the containment devices prior to implantation. The pack is then stored until implantation.
In another example, medicament containment devices may be associated with the implant by electrostatically charging the implant to a positive or negative charge and a group of medicament containment devices to the opposite charge. The implant and medicament containment devices are then sintered by heating them to a temperature below or just at the melting point of the medicament containment devices and bringing them in proximity to each other. The medicament containment devices then attach to the implant.
An orthopedist removes the orthopaedic implant from the pack and implants it into a patients body. After a period of time, the patient may experience an infection around the orthopaedic implant caused by bacterial colonies forming around the orthopaedic implant and seek medical attention to treat the infection. The orthopedist, or other user, uses an ultrasound energy source, such as a low intensity ultrasound bone healing system manufactured by Exogen™, outside the patient's body but in relative proximity to the location of the orthopaedic implant to introduce ultrasound energy to the orthopaedic implant area. The ultrasound energy source includes a dial that allows the user to select a frequency at which to release the energy.
The containment devices with an outer layer having a resonant frequency at the frequency of the applied energy degrade after exposure to the energy and expose the resorbable inner layer to the patient's body tissue. The resonant frequency of each containment device can be controlled by the size and type of material that the containment devices are made from. For example, some of the containment devices may also be made from calcium phosphate at different levels to provide containment devices that degrade at different ultrasound frequencies. Over a period of time, the resorbable inner layer degrades due to exposure to the patient's body tissue and time-releases the antibiotic medicament into the patient's body. The antibiotic medicament kills all or at least part of the bacterial colonies.
If the bacterial colonies return after a period of time, a user selects a second energy frequency on the ultrasound energy source and applies energy at the selected frequency to the orthopaedic implant area. Containment device outer layers that did not degrade upon exposure to the first energy frequency, but have a resonant frequency at the second energy frequency, degrade to expose the resorbable inner layer to the patient's body tissue. The resorbable inner layer degrades over a period of time due to exposure to the patient's body tissue and substantially releases the antibiotic medicament within the inner layer. This process may be repeated as necessary.
The foregoing description of the embodiments, including example embodiments, of the invention has been presented only for the purpose of illustration and description and is not intended to be exhaustive or to limit the invention to the precise forms disclosed. Numerous modifications and adaptations thereof will be apparent to those skilled in the art without departing from the spirit and scope of this invention.
The present application is a National Stage of International Application No. PCT/US2007/005533, filed Mar. 2, 2007, which claims priority to U.S. provisional patent application No. 60/778,778, entitled “Apparatus and Method for Dispensing a Medicament,” filed Mar. 3, 2006. The entire contents of each prior application are incorporated herein by reference.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US2007/005533 | 3/2/2007 | WO | 00 | 12/11/2009 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2007/103276 | 9/13/2007 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
3531561 | Trehu | Sep 1970 | A |
3636956 | Schneider | Jan 1972 | A |
3676401 | Henry | Jul 1972 | A |
3736646 | Schmitt et al. | Jun 1973 | A |
3797499 | Schneider | Mar 1974 | A |
4137921 | Okuzumi et al. | Feb 1979 | A |
4181983 | Kulkarni | Jan 1980 | A |
4281664 | Duggan | Aug 1981 | A |
4361153 | Slocum et al. | Nov 1982 | A |
4438253 | Casey et al. | Mar 1984 | A |
4513743 | van Arragon et al. | Apr 1985 | A |
4523591 | Kaplan et al. | Jun 1985 | A |
4539981 | Tunc | Sep 1985 | A |
4576158 | Boland | Mar 1986 | A |
4636215 | Schwartz | Jan 1987 | A |
4840632 | Kampner | Jun 1989 | A |
4858603 | Clemow et al. | Aug 1989 | A |
4938763 | Dunn et al. | Jul 1990 | A |
4950258 | Kawai et al. | Aug 1990 | A |
4952928 | Carroll et al. | Aug 1990 | A |
4990161 | Kampner | Feb 1991 | A |
5049591 | Hayashi et al. | Sep 1991 | A |
5108755 | Daniels et al. | Apr 1992 | A |
5110852 | Gogolewski et al. | May 1992 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5201738 | Scott et al. | Apr 1993 | A |
5201771 | Belykh et al. | Apr 1993 | A |
5258422 | Chang et al. | Nov 1993 | A |
5275601 | Gogolewski et al. | Jan 1994 | A |
5294395 | Broyer | Mar 1994 | A |
5309919 | Snell et al. | May 1994 | A |
5330477 | Crook | Jul 1994 | A |
5333624 | Tovey | Aug 1994 | A |
5337747 | Neftel | Aug 1994 | A |
5383931 | Hehli et al. | Jan 1995 | A |
5383935 | Shirkhanzadeh | Jan 1995 | A |
5407445 | Tautvydas et al. | Apr 1995 | A |
5417712 | Whittaker et al. | May 1995 | A |
5423334 | Jordan | Jun 1995 | A |
5437918 | Taniguchi et al. | Aug 1995 | A |
5441515 | Khosravi et al. | Aug 1995 | A |
5522817 | Sander et al. | Jun 1996 | A |
5525706 | Gruber et al. | Jun 1996 | A |
5527337 | Stack et al. | Jun 1996 | A |
5527341 | Gogolewski et al. | Jun 1996 | A |
5533519 | Radke et al. | Jul 1996 | A |
5584836 | Ballintyn et al. | Dec 1996 | A |
5630835 | Brownlee | May 1997 | A |
5633002 | Stricker et al. | May 1997 | A |
5634936 | Linden et al. | Jun 1997 | A |
5660846 | Cheikh | Aug 1997 | A |
5676146 | Scarborough | Oct 1997 | A |
5716410 | Wang et al. | Feb 1998 | A |
5716413 | Walter et al. | Feb 1998 | A |
5733330 | Cox | Mar 1998 | A |
5735887 | Barreras, Sr. et al. | Apr 1998 | A |
5760118 | Sinclair et al. | Jun 1998 | A |
5766239 | Cox | Jun 1998 | A |
5766618 | Laurencin et al. | Jun 1998 | A |
5792400 | Talja et al. | Aug 1998 | A |
5833603 | Kovacs et al. | Nov 1998 | A |
5836989 | Shelton | Nov 1998 | A |
5873843 | Draper | Feb 1999 | A |
5893850 | Cachia | Apr 1999 | A |
5904658 | Niederauer et al. | May 1999 | A |
5904708 | Goedeke | May 1999 | A |
5908918 | Chen et al. | Jun 1999 | A |
5935172 | Ochoa et al. | Aug 1999 | A |
6013080 | Khalili | Jan 2000 | A |
6022352 | Vandewalle | Feb 2000 | A |
6071312 | Lampe et al. | Jun 2000 | A |
6077989 | Kandel et al. | Jun 2000 | A |
6187008 | Hamman | Feb 2001 | B1 |
6203573 | Walter et al. | Mar 2001 | B1 |
6206881 | Frigg et al. | Mar 2001 | B1 |
6248108 | Tormala et al. | Jun 2001 | B1 |
6248430 | Toyoda et al. | Jun 2001 | B1 |
6281262 | Shikinami | Aug 2001 | B1 |
6344496 | Niederauer et al. | Feb 2002 | B1 |
6375465 | Engman et al. | Apr 2002 | B1 |
6423062 | Enayati | Jul 2002 | B2 |
6425923 | Stalcup et al. | Jul 2002 | B1 |
6436136 | Flodin et al. | Aug 2002 | B1 |
6503278 | Pohjonen et al. | Jan 2003 | B1 |
6511511 | Slivka et al. | Jan 2003 | B1 |
6514286 | Leatherbury et al. | Feb 2003 | B1 |
6565606 | Bruce et al. | May 2003 | B1 |
6605090 | Trieu et al. | Aug 2003 | B1 |
6675044 | Chen | Jan 2004 | B2 |
6719935 | Tunc | Apr 2004 | B2 |
6738671 | Christophersom et al. | May 2004 | B2 |
6764446 | Wolinsky et al. | Jul 2004 | B2 |
6766200 | Cox | Jul 2004 | B2 |
6783712 | Slivka et al. | Aug 2004 | B2 |
6790372 | Roy et al. | Sep 2004 | B2 |
6793659 | Putnam | Sep 2004 | B2 |
6819247 | Birnbach et al. | Nov 2004 | B2 |
6834436 | Townsend et al. | Dec 2004 | B2 |
6841111 | Rickner et al. | Jan 2005 | B2 |
6881766 | Hain | Apr 2005 | B2 |
6908466 | Bonutti et al. | Jun 2005 | B1 |
6916321 | TenHuisen et al. | Jul 2005 | B2 |
6926670 | Rich et al. | Aug 2005 | B2 |
6939299 | Petersen et al. | Sep 2005 | B1 |
6968743 | Rich et al. | Nov 2005 | B2 |
7005543 | Zhang | Feb 2006 | B2 |
7027871 | Burnes et al. | Apr 2006 | B2 |
7033603 | Nelson et al. | Apr 2006 | B2 |
7034694 | Yamaguchi et al. | Apr 2006 | B2 |
7090676 | Huebner et al. | Aug 2006 | B2 |
7097662 | Evans, III et al. | Aug 2006 | B2 |
7151914 | Brewer | Dec 2006 | B2 |
7209790 | Thompson et al. | Apr 2007 | B2 |
7212133 | Goetz et al. | May 2007 | B2 |
7261716 | Strobel et al. | Aug 2007 | B2 |
7261734 | Gellman et al. | Aug 2007 | B2 |
7333013 | Berger | Feb 2008 | B2 |
7381223 | Kovacevic | Jun 2008 | B2 |
7559951 | DiSilvestro et al. | Jul 2009 | B2 |
7729758 | Haller et al. | Jun 2010 | B2 |
7794495 | Gale et al. | Sep 2010 | B2 |
8007450 | Williams | Aug 2011 | B2 |
8267990 | Gale et al. | Sep 2012 | B2 |
8394488 | Davé et al. | Mar 2013 | B2 |
8722783 | Rose et al. | May 2014 | B2 |
8828419 | Davé et al. | Sep 2014 | B2 |
8870945 | Dave et al. | Oct 2014 | B2 |
9000066 | Brown et al. | Apr 2015 | B2 |
9120919 | Brown | Sep 2015 | B2 |
9308293 | Brown et al. | Apr 2016 | B2 |
20010021873 | Stinson | Sep 2001 | A1 |
20010034528 | Foerster et al. | Oct 2001 | A1 |
20020022588 | Wilkie et al. | Feb 2002 | A1 |
20020029041 | Hover et al. | Mar 2002 | A1 |
20020029043 | Ahrens et al. | Mar 2002 | A1 |
20020082683 | Stinson et al. | Jun 2002 | A1 |
20020082685 | Sirhan | Jun 2002 | A1 |
20030045941 | Lewallen | Mar 2003 | A1 |
20030114937 | Leatherbury et al. | Jun 2003 | A1 |
20030125745 | Tseng et al. | Jul 2003 | A1 |
20030139812 | Garcia et al. | Jul 2003 | A1 |
20040010313 | Aston | Jan 2004 | A1 |
20040019356 | Fraser et al. | Jan 2004 | A1 |
20040019386 | Ferree | Jan 2004 | A1 |
20040030379 | Hamm | Feb 2004 | A1 |
20040059336 | Lombardo et al. | Mar 2004 | A1 |
20040077073 | Schindler et al. | Apr 2004 | A1 |
20040092818 | Weaver et al. | May 2004 | A1 |
20040106734 | Rose | Jun 2004 | A1 |
20040116837 | Yamaguchi et al. | Jun 2004 | A1 |
20040152972 | Hunter | Aug 2004 | A1 |
20040156878 | Rezania et al. | Aug 2004 | A1 |
20040176815 | Janzig et al. | Sep 2004 | A1 |
20040204647 | Grupp et al. | Oct 2004 | A1 |
20040220668 | Eisermann et al. | Nov 2004 | A1 |
20040242722 | Rose et al. | Dec 2004 | A1 |
20040243129 | Moumene et al. | Dec 2004 | A1 |
20050008672 | Winterbottom et al. | Jan 2005 | A1 |
20050010139 | Aminian et al. | Jan 2005 | A1 |
20050013793 | Beckman et al. | Jan 2005 | A1 |
20050021029 | Trieu et al. | Jan 2005 | A1 |
20050055027 | Yeung et al. | Mar 2005 | A1 |
20050085313 | Nishitani | Apr 2005 | A1 |
20050085812 | Sherman et al. | Apr 2005 | A1 |
20050099290 | Govari | May 2005 | A1 |
20050101833 | Hsu et al. | May 2005 | A1 |
20050107886 | Crabtree et al. | May 2005 | A1 |
20050131397 | Levin | Jun 2005 | A1 |
20050159812 | Dinger, III et al. | Jul 2005 | A1 |
20050165128 | Cohn et al. | Jul 2005 | A1 |
20050177245 | Leatherbury et al. | Aug 2005 | A1 |
20050187555 | Biedermann et al. | Aug 2005 | A1 |
20050234555 | Sutton et al. | Oct 2005 | A1 |
20050247319 | Berger | Nov 2005 | A1 |
20050273106 | Von Oepen | Dec 2005 | A1 |
20050288727 | Penner | Dec 2005 | A1 |
20060009656 | Zhang | Jan 2006 | A1 |
20060047283 | Evans, III et al. | Mar 2006 | A1 |
20060052782 | Morgan et al. | Mar 2006 | A1 |
20060058627 | Flaherty et al. | Mar 2006 | A1 |
20060067973 | Schachter | Mar 2006 | A1 |
20060069447 | DiSilvestro et al. | Mar 2006 | A1 |
20060079900 | Mathieu et al. | Apr 2006 | A1 |
20060111291 | DiMauro et al. | May 2006 | A1 |
20060129050 | Martinson et al. | Jun 2006 | A1 |
20060136071 | Maspero et al. | Jun 2006 | A1 |
20060161159 | Dreyfuss et al. | Jul 2006 | A1 |
20060178748 | Dinger, III et al. | Aug 2006 | A1 |
20060188547 | S. Bezwada | Aug 2006 | A1 |
20060190080 | Danoff et al. | Aug 2006 | A1 |
20060200031 | White et al. | Sep 2006 | A1 |
20060235410 | Ralph et al. | Oct 2006 | A1 |
20060271112 | Martinson et al. | Nov 2006 | A1 |
20060271199 | Johnson | Nov 2006 | A1 |
20070041950 | Leatherbury et al. | Feb 2007 | A1 |
20070043376 | Leatherbury et al. | Feb 2007 | A1 |
20070078497 | Vandanacker | Apr 2007 | A1 |
20070089518 | Ericson et al. | Apr 2007 | A1 |
20070123938 | Haller et al. | May 2007 | A1 |
20070128154 | Hadba et al. | Jun 2007 | A1 |
20070129769 | Bourget et al. | Jun 2007 | A1 |
20070134305 | Zilberman | Jun 2007 | A1 |
20070185488 | Pohjonen et al. | Aug 2007 | A1 |
20070191963 | Winterbottom et al. | Aug 2007 | A1 |
20070219639 | Otto et al. | Sep 2007 | A1 |
20070270691 | Bailey et al. | Nov 2007 | A1 |
20070270833 | Bonutti et al. | Nov 2007 | A1 |
20070276383 | Rayhack | Nov 2007 | A1 |
20080045627 | Rose | Feb 2008 | A1 |
20080085297 | Dave et al. | Apr 2008 | A1 |
20080086199 | Dave et al. | Apr 2008 | A1 |
20080154310 | White et al. | Jun 2008 | A1 |
20080177291 | Jensen et al. | Jul 2008 | A1 |
20080183221 | Burdilis | Jul 2008 | A1 |
20080300597 | Morgan et al. | Dec 2008 | A1 |
20100016985 | Rabiei | Jan 2010 | A1 |
20100069547 | Brown et al. | Mar 2010 | A1 |
20100137491 | Rose et al. | Jun 2010 | A1 |
20100152621 | Janna et al. | Jun 2010 | A1 |
20110098803 | Gale et al. | Apr 2011 | A1 |
Number | Date | Country |
---|---|---|
202006009013 | Aug 2006 | DE |
0062459 | Oct 1982 | EP |
1099415 | May 2001 | EP |
1541095 | Jun 2005 | EP |
1642550 | Apr 2006 | EP |
1660146 | May 2006 | EP |
1704893 | Sep 2006 | EP |
2330078 | Apr 1999 | GB |
WO9609014 | Mar 1996 | WO |
WO9626678 | Sep 1996 | WO |
WO9629007 | Sep 1996 | WO |
WO9720512 | Jun 1997 | WO |
WO0018317 | Apr 2000 | WO |
WO0019888 | Apr 2000 | WO |
WO0030534 | Jun 2000 | WO |
WO0119248 | Jun 2001 | WO |
WO02058551 | Oct 2002 | WO |
WO02056763 | Nov 2002 | WO |
WO03008570 | Jan 2003 | WO |
WO2004052453 | Jun 2004 | WO |
WO2004052456 | Jun 2004 | WO |
WO2005018684 | Mar 2005 | WO |
WO2005018698 | Mar 2005 | WO |
WO2005084544 | Sep 2005 | WO |
WO2005104997 | Nov 2005 | WO |
WO2005120203 | Dec 2005 | WO |
WO2006045607 | May 2006 | WO |
WO2006055547 | May 2006 | WO |
WO2006089069 | Aug 2006 | WO |
WO2006094273 | Sep 2006 | WO |
WO2006131302 | Dec 2006 | WO |
WO2007009088 | Jan 2007 | WO |
WO2007009123 | Jan 2007 | WO |
WO2007025191 | Mar 2007 | WO |
WO2007061890 | May 2007 | WO |
WO2007069251 | Jun 2007 | WO |
WO2007086832 | Aug 2007 | WO |
WO2007138062 | Dec 2007 | WO |
WO2008022136 | Feb 2008 | WO |
WO2008044011 | Apr 2008 | WO |
WO2010004261 | Jan 2010 | WO |
WO2010045473 | Apr 2010 | WO |
WO2011082152 | Jul 2011 | WO |
WO2013012731 | Jan 2013 | WO |
Entry |
---|
International Search Report and Written Opinion for International Application No. PCT/US2012/046694, dated Jan. 28, 2013. |
International Search Report for International Application No. PCT/US2006/033326, dated Dec. 13, 2006. |
International Preliminary Report on Patentability for International Application No. PCT/US2006/033326, dated Feb. 28, 2008. |
Kishida, A., et al., “Formulation-Assisted Biodegradable Polymer Matrices,” Communications to the Editor, Chem. Pharm. Bull. 37(7) 1954-1956 (1989). |
Oyama, H.T., et al., “Rapid controlled hydrolytic degradation of poly(L-lactic acid) by blending with poly(aspartic acid-co-L-lactide),” Polymer Degradation and Stability, 94 (2009) 1419-1426. |
Number | Date | Country | |
---|---|---|---|
20100094195 A1 | Apr 2010 | US |
Number | Date | Country | |
---|---|---|---|
60778778 | Mar 2006 | US |